Fig. 3From: Generation of stable PDX derived cell lines using conditional reprogrammingCR-PDX cell lines are amenable to in vivo preclinical applications. a. Re-implanted CR-HLXF-036LN and CR-LG0567F cells formed tumors in NSG mice (open symbols) and maintained growth kinetics of parental tumor (closed symbols). CR-HLXF-036LN maintained sensitivity to Savolitinib (25 mg/kg, QD, n = 2) and CR-LG0567F maintained sensitivity to Selumetinib (25 mg/kg, BID, n = 3) similar to parental tumors (dotted lines, n = 10 for HLXF-036LN and n = 9 for LG0567F). Mean ± error shown for each model. b Implanted CR-PDX tumors maintain pharmacodynamic response to targeted agents, similar to parental tumors. c Subcutaneously implanted CR-PDX cells produce tumors with histology similar to parental PDX tumor. Representative images shown (n = 2)Back to article page